Minretumomab

Minretumomab
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetTAG-72
Clinical data
Other namesCC49
ATC code
Identifiers
CAS Number
ChemSpider
  • none
UNII
 NY (what is this?)  (verify)

Minretumomab (CC49) is a mouse monoclonal antibody[1] that was designed for the treatment of cancers that express the TAG-72 antigen. This includes breast, colon, lung, and pancreatic cancers.[2][3] Apparently, it never got past Phase I clinical trials for this purpose.[4]

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 13 (3). 1999.
  2. ^ "TAG-72 antigen". NCI Dictionary of Cancer Terms. National Cancer Institute. 2011-02-02.
  3. ^ Scott AM, Wolchok JD, Old LJ (March 2012). "Antibody therapy of cancer". Nature Reviews. Cancer. 12 (4): 278–87. doi:10.1038/nrc3236. PMID 22437872. S2CID 205469234.
  4. ^ "Studies found for: CC49". ClinicalTrials.gov.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.